Suppr超能文献

通过磷酸化靶向嵌合体(PhosTACs)对tau蛋白进行靶向去磷酸化作为一种治疗方式。

Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality.

作者信息

Hu Zhenyi, Chen Po-Han, Li Wenxue, Douglas Todd, Hines John, Liu Yansheng, Crews Craig M

机构信息

Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut 06511, United States.

Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan City 701, Taiwan.

出版信息

J Am Chem Soc. 2023 Feb 8. doi: 10.1021/jacs.2c11706.

Abstract

Microtubule-associated protein tau is essential for microtubule assembly and stabilization. Hyperphosphorylation of the microtubule-associated protein tau plays an important pathological role in the development of Alzheimer's disease and other tauopathies. studies using kinase inhibitors suggest that reducing tau phosphorylation levels has therapeutic potential; however, such approaches showed limited benefits. We sought to further develop our phosphorylation targeting chimera (PhosTAC) technology to specifically induce tau dephosphorylation. Herein, we use small molecule-based PhosTACs to recruit tau to PP2A, a native tau phosphatase. PhosTACs induced the formation of a stable ternary complex, leading to rapid, efficient, and sustained tau dephosphorylation, which also correlated with the enhanced downregulation of tau protein. Mass spectrometry data validated that PhosTACs downregulated multiple phosphorylation sites of tau. We believe that PhosTAC possesses several advantages over current strategies to modulate tau phosphorylation and represents a new avenue for disease-modifying therapies for tauopathies.

摘要

微管相关蛋白tau对微管组装和稳定至关重要。微管相关蛋白tau的过度磷酸化在阿尔茨海默病和其他tau蛋白病的发展中起重要病理作用。使用激酶抑制剂的研究表明,降低tau蛋白磷酸化水平具有治疗潜力;然而,这些方法的益处有限。我们试图进一步开发我们的磷酸化靶向嵌合体(PhosTAC)技术,以特异性诱导tau蛋白去磷酸化。在此,我们使用基于小分子的PhosTACs将tau蛋白招募到天然tau蛋白磷酸酶PP2A。PhosTACs诱导形成稳定的三元复合物,导致快速、有效和持续的tau蛋白去磷酸化,这也与tau蛋白的下调增强相关。质谱数据验证了PhosTACs下调了tau蛋白的多个磷酸化位点。我们认为,与目前调节tau蛋白磷酸化的策略相比,PhosTAC具有几个优点,代表了tau蛋白病疾病修饰治疗的新途径。

相似文献

2
EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling.
Sci Adv. 2024 Mar 29;10(13):eadj7251. doi: 10.1126/sciadv.adj7251. Epub 2024 Mar 27.
3
Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs).
ACS Chem Biol. 2021 Dec 17;16(12):2808-2815. doi: 10.1021/acschembio.1c00693. Epub 2021 Nov 15.
4
Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer's disease and related tauopathies.
Sci Bull (Beijing). 2024 Apr 30;69(8):1137-1152. doi: 10.1016/j.scib.2024.01.019. Epub 2024 Jan 19.
5
A new tau dephosphorylation-targeting chimera for the treatment of tauopathies.
Acta Pharmacol Sin. 2024 Nov;45(11):2267-2276. doi: 10.1038/s41401-024-01326-4. Epub 2024 Jul 2.
6
A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies.
Signal Transduct Target Ther. 2021 Jul 14;6(1):269. doi: 10.1038/s41392-021-00669-2.
7
Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau.
PLoS One. 2011;6(6):e21521. doi: 10.1371/journal.pone.0021521. Epub 2011 Jun 23.
8
Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites.
J Biol Chem. 2013 Mar 15;288(11):7968-7977. doi: 10.1074/jbc.M112.433326. Epub 2013 Jan 28.
9
Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
Curr Protein Pept Sci. 2022;23(3):129-132. doi: 10.2174/1389203723666220519154229.
10
Protein phosphatase 2A and tau: an orchestrated 'Pas de Deux'.
FEBS Lett. 2018 Apr;592(7):1079-1095. doi: 10.1002/1873-3468.12907. Epub 2017 Nov 19.

引用本文的文献

1
PROTAC Technology as a New Tool for Modern Pharmacotherapy.
Molecules. 2025 May 11;30(10):2123. doi: 10.3390/molecules30102123.
3
Turnover atlas of proteome and phosphoproteome across mouse tissues and brain regions.
Cell. 2025 Apr 17;188(8):2267-2287.e21. doi: 10.1016/j.cell.2025.02.021. Epub 2025 Mar 20.
4
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies.
ACS Pharmacol Transl Sci. 2025 Feb 10;8(3):654-672. doi: 10.1021/acsptsci.4c00733. eCollection 2025 Mar 14.
5
Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities.
Alzheimers Dement. 2025 Mar;21(3):e70048. doi: 10.1002/alz.70048.
6
Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer.
Front Cell Dev Biol. 2024 Dec 24;12:1436033. doi: 10.3389/fcell.2024.1436033. eCollection 2024.
7
Targeted protein degradation with bifunctional molecules as a novel therapeutic modality for Alzheimer's disease & beyond.
Neurotherapeutics. 2025 Apr;22(3):e00499. doi: 10.1016/j.neurot.2024.e00499. Epub 2024 Dec 4.
8
Roles of posttranslational modifications in lipid metabolism and cancer progression.
Biomark Res. 2024 Nov 18;12(1):141. doi: 10.1186/s40364-024-00681-y.
9
An Extensive Atlas of Proteome and Phosphoproteome Turnover Across Mouse Tissues and Brain Regions.
bioRxiv. 2024 Oct 17:2024.10.15.618303. doi: 10.1101/2024.10.15.618303.
10
A protein phosphatase 1 specific phatase rgeting eptide (PhosTAP) to identify the PP1 phosphatome.
Proc Natl Acad Sci U S A. 2024 Oct 29;121(44):e2415383121. doi: 10.1073/pnas.2415383121. Epub 2024 Oct 24.

本文引用的文献

1
Global estimates on the number of persons across the Alzheimer's disease continuum.
Alzheimers Dement. 2023 Feb;19(2):658-670. doi: 10.1002/alz.12694. Epub 2022 Jun 2.
3
Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs).
ACS Chem Biol. 2021 Dec 17;16(12):2808-2815. doi: 10.1021/acschembio.1c00693. Epub 2021 Nov 15.
4
Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.
Chembiochem. 2022 Jan 19;23(2):e202100270. doi: 10.1002/cbic.202100270. Epub 2021 Sep 23.
6
A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies.
Signal Transduct Target Ther. 2021 Jul 14;6(1):269. doi: 10.1038/s41392-021-00669-2.
8
Tau strains shape disease.
Acta Neuropathol. 2021 Jul;142(1):57-71. doi: 10.1007/s00401-021-02301-7. Epub 2021 Apr 8.
10
Targeted Degradation of Oncogenic KRAS by VHL-Recruiting PROTACs.
ACS Cent Sci. 2020 Aug 26;6(8):1367-1375. doi: 10.1021/acscentsci.0c00411. Epub 2020 Jul 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验